N-[3-aminopropyl(propyl)amino]-N-hydroxynitrous amide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[3-aminopropyl(propyl)amino]-N-hydroxynitrous amide
• 化学式: C₆H₁₆N₄O₂
• mdl: MFCD00801020
• 分子量: 176.22
• InChiKey: CXQCOPWRDNFJDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  82.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] MELATONIN DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL DYSFUNCTIONS<br/>[FR] DERIVES DE MELATONINE ET LEUR UTILISATION DANS LE TRAITEMENT DE DYSFONCTIONNEMENTS NEUROLOGIQUES
  申请人：FAUST PHARMACEUTICALS

  公开号：WO2004085392A1

  公开（公告）日：2004-10-07

  The present invention relates to compounds of the general formula (1): wherein R1, R2, R3, R4 and R5 are H or a moiety of the formula : -(R6)n-R7; with R6 is a is an alkyl chain and R7 is, a moiety selected in the group consisting of -Cn,H2n2,+I, a cycloalkyl moiety, -N(Cn,H2n,+I)(Cn,H2n,+1), -NH-cycloalkyl, -O(Cn,H2n'+I), -0-cycloalkyl, =O, =S, -NO2, -I, -Br, -Cl, -F, -CF3, -OCF3, -COOH, -S03H, -P03H2, -CN, A3 and A4 are, C, N,O or S;m is from 0 to 2; and to their use for the treatment and/or prevention of diseases and conditions mediated by the imbalance of acetylcholine, and for treating and/or preventing glutamate excitotoxicity.

  本发明涉及通式（1）的化合物：其中R1、R2、R3、R4和R5为H或具有以下结构的基团：-(R6)n-R7；其中R6是烷基链，R7是在由-CnH2n2，+I组成的基团中选择的一个基团，是环烷基基团，-N(CnH2n+I)(CnH2n+1)，-NH-环烷基，-O(CnH2n'+I)，-O-环烷基，=O，=S，-NO2，-I，-Br，-Cl，-F，-CF3，-O ，-COOH，-SO3H，-PO3H2，-CN中的一种；A3和A4为C、N、O或S；m为0到2；以及它们用于治疗和/或预防由乙酰胆碱失衡介导的疾病和症状，以及用于治疗和/或预防谷氨酸兴奋毒性。
• Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
  申请人：Nastech Pharmaceutical Company Inc.

  公开号：US20040157777A1

  公开（公告）日：2004-08-12

  Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.

  描述了包含至少一种Y2受体结合肽（如肽YY（PYY）、神经肽Y（NPY）或胰岛素肽（PP））和一种或多种黏膜传递增强剂的药物组合物和方法，以增强肽YY在鼻黏膜中的传递，用于治疗哺乳动物主体中的多种疾病和病况，包括肥胖。
• Intranasal administration of glucose-regulating peptides
  申请人：Quay C. Steven

  公开号：US20050143303A1

  公开（公告）日：2005-06-30

  Pharmaceutical compositions and methods are described comprising at least one glucose-regulating peptide, such as amylin, glucagon-like peptide-1 (GLP), pramlintide or exendin-4 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the amylin, for treating a variety of diseases and conditions in mammalian subjects, including obesity and diabetes mellitus.

  本文介绍了一种药物组合和方法，其中包括至少一种调节葡萄糖的肽类，如降淀粉样肽、胰高血糖素样肽-1（GLP）、普拉林肽或外肽-4，以及一种或多种黏膜传递增强剂，以增强降淀粉样肽在鼻黏膜上的传递，用于治疗哺乳动物主体中的多种疾病和病况，包括肥胖和糖尿病。
• NO donors, combination products and uses as modulators of neurotransmitter release
  申请人：Faust Pharmaceuticals

  公开号：EP1462103A1

  公开（公告）日：2004-09-29

  The present invention relates to compounds of the general formula (I) or (II):    wherein: R1, R2, R3, R4, R5 and R10 are, independently from one another, H or a moiety of the following general formula : -(R6)n-R7, with R6 is an alkyl chain and R7 is, a moiety selected in the group consisting of -Cn'H2n'+1, a cycloalkyl moiety, -N(Cn'H2n'+1)(Cn'H2n'+1), -NH-cycloalkyl, -O(Cn'H2n'+1), -O-cycloalkyl, =O, =S, -NO2, , -I, -Br, -Cl, -F, -CF3, -OCF3, -COOH, -SO3H, -PO3H2, -CN, A3, A4, A8 and A9 are C, N, O and S, m is 0 to 2, n is 0 to 6, and to their use for the treatment and/or prevention of diseases and conditions mediated by the imbalance of acetylcholine, and for treating and/or preventing glutamate excitotoxicity.

  本发明涉及通式（I）或（II）的化合物：   其中：R1、R2、R3、R4、R5和R10独立地为H或以下述通式的基团：-(R6)n-R7，其中R6是烷基链，R7是从以下组成的基团中选择的一种：-Cn'H2n'+1，环烷基基团，-N(Cn'H2n'+1)(Cn'H2n'+1)，-NH-环烷基，-O(Cn'H2n'+1)，-O-环烷基，=O，=S，-NO2，-I，-Br，-Cl，-F，-CF3，-O ，-COOH，-SO3H，-PO3H2，-CN，A3，A4，A8和A9为C，N，O和S，m为0到2，n为0到6，以及它们用于治疗和/或预防由乙酰胆碱失衡介导的疾病和病况，以及用于治疗和/或预防谷氨酸兴奋毒性。
• COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF PYY PEPTIDE
  申请人：Quay C. Steven

  公开号：US20070129299A1

  公开（公告）日：2007-06-07

  Pharmaceutical compositions are described comprising PYY(3-36) (SEQ ID NO: 2), a solubilizing agent, a lipid, a polyol.

  本文描述了一种药物组合物，其中包含PYY(3-36) (序列ID号：2)，一种溶解剂，一种脂质和一种多元醇。